Secondary prevention lipid management following ACS: a missed opportunity?
作者信息
Khan Zahid, Rakhit Roby
机构信息
Specialist Registrar in Cardiology Royal Free Hospital, Pond Street, London NW3 2QG.
Professor of Cardiology Royal Free Hospital, Pond Street, London NW3 2QG.
出版信息
Br J Cardiol. 2022 Nov 9;29(4):35. doi: 10.5837/bjc.2022.035. eCollection 2022.
Abstract
摘要
相似文献
1
Secondary prevention lipid management following ACS: a missed opportunity?
Br J Cardiol. 2022 Nov 9;29(4):35. doi: 10.5837/bjc.2022.035. eCollection 2022.
2
Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation.
Curr Atheroscler Rep. 2021 Oct 21;23(12):77. doi: 10.1007/s11883-021-00976-7.
3
Comparison of the American College of Cardiology/American Heart Association and the European Society of Cardiology guidelines for the management of patients with non-ST-segment elevation acute coronary syndromes.
Coron Artery Dis. 2017 Jun;28(4):294-300. doi: 10.1097/MCA.0000000000000472.
4
New National Institute for Health and Care Excellence guidance for hypertension: a review and comparison with the US and European guidelines.
Heart. 2024 Feb 23;110(6):399-401. doi: 10.1136/heartjnl-2022-322118.
5
Major Global Coronary Artery Calcium Guidelines.
JACC Cardiovasc Imaging. 2023 Jan;16(1):98-117. doi: 10.1016/j.jcmg.2022.06.018. Epub 2022 Sep 14.
6
Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
JAMA Cardiol. 2019 Nov 1;4(11):1131-1138. doi: 10.1001/jamacardio.2019.3665.
7
Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
JAMA Cardiol. 2022 Aug 1;7(8):836-843. doi: 10.1001/jamacardio.2022.1876.
8
Head-to-Head Comparison and Temporal Trends of Cardiac MRI Recommendations in ESC versus ACC/AHA Guidelines: A Systematic Review and Meta-Analysis.
Radiol Cardiothorac Imaging. 2024 Jun;6(3):e230271. doi: 10.1148/ryct.230271.
9
Isolated Diastolic Hypertension in the UK Biobank: Comparison of ACC/AHA and ESC/NICE Guideline Definitions.
Hypertension. 2020 Sep;76(3):699-706. doi: 10.1161/HYPERTENSIONAHA.120.15286. Epub 2020 Jul 27.
10
Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort.
JAMA. 2014 Apr 9;311(14):1416-23. doi: 10.1001/jama.2014.2632.
引用本文的文献
1
Optimisation of lipid-lowering therapy post-Acute Coronary Syndromes: a multidisciplinary, cross-interface novel pharmacy care model within a local cardiac rehabilitation centre.
J Pharm Policy Pract. 2025 Jul 8;18(1):2523934. doi: 10.1080/20523211.2025.2523934. eCollection 2025.
2
Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review.
Cardiovasc Drugs Ther. 2024 Jun 29. doi: 10.1007/s10557-024-07587-9.
本文引用的文献
1
Evaluation of a lipid management pathway within a local cardiac rehabilitation service.
Br J Cardiol. 2022 Nov 9;29(4):34. doi: 10.5837/bjc.2022.034. eCollection 2022.
2
Patient delay prior to care-seeking in acute myocardial infarction during the outbreak of the coronavirus SARS-CoV2 pandemic.
Eur J Cardiovasc Nurs. 2021 Nov 28;20(8):752-759. doi: 10.1093/eurjcn/zvab087.
3
Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives.
Atheroscler Suppl. 2020 Dec;42:e59-e64. doi: 10.1016/j.atherosclerosissup.2021.01.010.
4
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.
Atheroscler Suppl. 2020 Dec;42:e49-e58. doi: 10.1016/j.atherosclerosissup.2021.01.009.
5
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
6
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries.
Atherosclerosis. 2019 Jun;285:135-146. doi: 10.1016/j.atherosclerosis.2019.03.014. Epub 2019 Apr 24.
7
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
8
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.
9
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Circulation. 2018 Aug 21;138(8):756-766. doi: 10.1161/CIRCULATIONAHA.118.034309.
10
The Risk of Cardiovascular Events After an Acute Coronary Event Remains High, Especially During the First Year, Despite Revascularization.
Rev Esp Cardiol (Engl Ed). 2016 Jan;69(1):11-8. doi: 10.1016/j.rec.2015.06.015. Epub 2015 Sep 3.
Zotero 插件